Company: DRTSW
Filing Date: 2025-03-12
Form Type: 20-F
Source: 0001213900-25-023187
Chunk: 229

Company: Alpha Tau Medical Ltd.
Filing Date: 2025-03-12
Form: 20-F
Item: Item 6
Chunk 229
---
 and may take all actions that are not specifically granted to our shareholders or to executive management. Our Chief Executive
Officer (referred to as a “general manager” under the Companies Law) is responsible for our day-to-day management. Our Chief
Executive Officer is appointed by, and serves at the discretion of, our board of directors, subject to the employment or consulting agreement
that we have entered into with him. All other executive officers are appointed by the Chief Executive Officer, subject to applicable corporate
approvals, and are subject to the terms of any applicable employment or consulting agreements that we may enter into with them.

We comply with the rules of
Nasdaq requiring that a majority of our directors are independent. Our board of directors has determined that all of our directors, other
than Uzi Sofer and Michael Avruch are independent under such rules.

Under our Articles, the number
of directors on our board of directors will be no less than three and no more than eleven, divided into three classes with staggered three-year
terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire
board of directors. At each annual general meeting of our shareholders, the election or re-election of directors following the expiration
of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general
meeting following such election or re-election. Therefore, at each annual general meeting, the term of office of only one class of directors
expires.

Our directors are divided
among the three classes as follows:

  the Class I directors are Alan Adler and S. Morry Blumenfeld, and their terms will expire at the annual general meeting of shareholders to be held in 2025;  

  the Class II directors are David Milch and Ruth Alon, and their terms will expire at our annual meeting of shareholders to be held in 2026; and  

  the Class III directors are Michael Avruch, Maya Netser and Uzi Sofer, and their term will expire at our annual meeting of shareholders to be held in 2027.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────

Our directors will generally
be appointed by a simple majority vote of holders of our ordinary shares, participating and voting (in person or by proxy) at an annual
general meeting of our shareholders, provided that (i